Lapatinib Teva (Lapatinib)

Lapatinib blocks the intracellular tyrosine kinase activity of HER2 (ErbB2) and EGFR (ErbB1). By preventing receptor autophosphorylation, it shuts down downstream signaling pathways such as MAPK and PI3K/AKT, which are essential for tumor cell growth and survival.

The dose of Lapatinib Teva is individualized by the prescribing oncologist based on the specific cancer indication, combination regimen, patient weight, liver function, and other clinical factors. No fixed dosing can be provided without a medical prescription.

Safety data for Lapatinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk, and this decision should be made by the treating physician.

To order Lapatinib Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lapatinib is a small‑molecule tyrosine kinase inhibitor that targets both HER2 and EGFR, whereas monoclonal antibodies such as trastuzumab target only the extracellular HER2 domain. Lapatinib can be combined with chemotherapy or hormonal therapy and offers an oral administration route, providing a different therapeutic option within the HER2‑targeted class.

Lapatinib tablets should be stored at or below 25 °C, in the original container, protected from moisture and light. Do not store in bathrooms or near heat sources. Keep out of reach of children and handle with dry hands to avoid tablet degradation.

Lapatinib is taken orally, usually once daily, with or without food as directed by the prescriber. Tablets should be swallowed whole with a full glass of water. Patients should follow the specific dosing schedule provided by their oncologist.

The most serious risks include hepatotoxicity, QT‑interval prolongation that can lead to life‑threatening arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, and interstitial lung disease. Patients should be monitored regularly for liver enzymes, cardiac rhythm and any signs of severe skin or respiratory problems.

Lapatinib should not be used in patients with known hypersensitivity to the drug, in those taking strong CYP3A4 inhibitors or inducers without medical supervision, and in individuals with uncontrolled cardiac disease, significant hepatic impairment, or a baseline QTc interval >450 ms. Contraindications are determined by the treating physician.